Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only a subset of safety-related claims is supported by the provided label excerpts. Most efficacy/indication, formulation/dosing (25 mg starting dose), mechanism, brand/manufacturer, and market-availability/patent claims are unsupported by the supplied prescribing information.
Category Scores
Accurate Statements
Quetiapine fumarate carries a potential risk of increased mortality in elderly patients with dementia-related psychosis.
Supported by Boxed Warning section (increased mortality in elderly patients with dementia-related psychosis) via provided label excerpt under 5.1.
Quetiapine fumarate can cause tardive dyskinesia.
Supported by Warning/Precaution 5.6 excerpt describing potentially irreversible dyskinetic movements in patients treated with antipsychotic drugs including quetiapine.
Quetiapine fumarate can cause metabolic changes.
Supported by Warning/Precaution 5.5 excerpt stating atypical antipsychotics are associated with metabolic changes including hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain.
Metabolic changes associated with quetiapine fumarate can include increased blood sugar.
Supported by 5.5 excerpt: metabolic changes include hyperglycemia/diabetes mellitus.
Metabolic changes associated with quetiapine fumarate can include increased cholesterol.
Supported by 5.5 excerpt (dyslipidemia) and 17 excerpts (elevations in total cholesterol/LDL-cholesterol).
Quetiapine fumarate carries a risk of neuroleptic malignant syndrome.
Supported by Warning/Precaution 5.4 excerpt describing NMS reported with antipsychotic drugs including quetiapine.
Abruptly stopping quetiapine fumarate is not recommended.
Supported by Warning/Precaution 5.19 excerpt: acute withdrawal symptoms described after abrupt cessation; gradual dose reduction is advised.
A gradual dose reduction is typically advised to avoid withdrawal symptoms.
Supported by 5.19 excerpt: 'Gradual dose reduction is advised.'
Common side effects of quetiapine fumarate include weight gain.
Partially supported by 5.5/17 excerpts indicating weight gain observed and that patients should receive regular monitoring of weight; however, the claim 'common side effects' is not explicitly supported as a ranked 'common adverse reaction' statement in the provided excerpts.
Unsupported Statements
Quetiapine fumarate 25 mg tablets are prescribed for the treatment of schizophrenia.
No label excerpt provided for Indications and Usage specifying schizophrenia treatment and no support for the specific '25 mg tablets' strength.
Quetiapine fumarate 25 mg tablets are prescribed for the treatment of bipolar disorder.
No label excerpt provided showing indication for bipolar disorder or linking it to the specific '25 mg tablets' strength.
For bipolar disorder, quetiapine fumarate is used to treat manic episodes.
No Indications and Usage excerpt provided that specifies treatment of manic episodes.
For bipolar disorder, quetiapine fumarate is used to treat depressive episodes associated with the condition.
No Indications and Usage excerpt provided that specifies treatment of bipolar depressive episodes.
Quetiapine fumarate is an atypical antipsychotic.
The provided label excerpts do not state 'atypical antipsychotic' in a way that clearly supports this general classification.
Quetiapine fumarate functions by modulating the activity of certain neurotransmitters in the brain.
Mechanism language in the provided excerpt states mechanism is unclear and could be mediated through dopamine and serotonin antagonism; the specific 'modulating activity' phrasing is not supported.
Quetiapine fumarate primarily affects dopamine.
The provided mechanism excerpt discusses D2 and 5HT2A antagonism and therefore suggests relevance, but does not explicitly state 'primarily affects dopamine.'
Quetiapine fumarate primarily affects serotonin.
The provided mechanism excerpt discusses 5HT2A antagonism, but does not explicitly state 'primarily affects serotonin.'
Seroquel is a brand name product of quetiapine fumarate.
No label excerpt provided supporting that 'Seroquel' is the brand name for quetiapine fumarate.
Seroquel is manufactured by AstraZeneca.
No label excerpt provided that identifies manufacturer of Seroquel.
Generic quetiapine fumarate is widely available.
No label excerpt provided supporting market availability statements.
Common side effects of quetiapine fumarate include drowsiness.
No adverse reaction excerpt provided that lists drowsiness as a common side effect.
Common side effects of quetiapine fumarate include dizziness.
No adverse reaction excerpt provided that lists dizziness as a common side effect; dizziness appears in the discontinuation symptom list (5.19), but that does not support 'common side effects' generally.
Common side effects of quetiapine fumarate include dry mouth.
No label excerpt provided supporting dry mouth as a common side effect.
Common side effects of quetiapine fumarate include constipation.
No label excerpt provided supporting constipation as a common side effect.
The 25 mg dosage is typically the starting dose for quetiapine fumarate.
No dosage excerpt provided specifying a 25 mg starting dose. Provided dosage excerpt relates to hepatic impairment with 'quetiapine extended-release tablets 50 mg/day.'
The 25 mg dose is used to initiate treatment.
Not supported by provided dosage excerpts.
The 25 mg dose is used for specific therapeutic goals.
Not supported by provided dosage excerpts.
Higher doses of quetiapine fumarate are generally used to manage more severe symptoms.
No dose/clinical correlation excerpt provided supporting this generalization.
Higher doses of quetiapine fumarate are generally used for different phases of bipolar disorder.
No dosage and administration excerpt provided that ties dose levels to bipolar phases.
The efficacy and side effect profile of quetiapine fumarate can vary with dose adjustments.
Not supported by provided label excerpts.
A gradual dose reduction is typically advised to avoid return of illness symptoms.
The provided label excerpt (5.19) advises gradual dose reduction to address withdrawal/discontinuation symptoms; it does not mention avoiding return of illness symptoms.
The patent exclusivity for Seroquel has expired.
No label excerpt provided supporting patent exclusivity status.
The expiration of Seroquel patent exclusivity allows for widespread availability of generic quetiapine fumarate.
No label excerpt provided supporting patent/availability relationships.
Contradictions
Important Omissions
Contraindications content (e.g., hypersensitivity to quetiapine/excipients) was not addressed in the extracted claims set.
Importance:
Moderate
Specific dosing/administration instructions for general starting dose (outside hepatic impairment) and for re-initiation/switching were not provided despite multiple dosage-related claims (25 mg starting dose).
Importance:
Moderate
Monitoring recommendations for metabolic parameters, weight, glucose, lipids, etc. were not included even though metabolic risks are claimed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While several safety warnings (mortality in dementia-related psychosis, NMS, metabolic changes, tardive dyskinesia, and withdrawal/discontinuation guidance) are supported, many other claims are unsupported or include potentially misleading specificity (e.g., '25 mg starting dose') and non-label statements (brand/patent/availability).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Most extracted claims are not supported by the provided FDA label excerpts, including indications, mechanism wording, brand/manufacturer/availability, and 25 mg dosing assertions.
Suggested Improvement
Remove or revise unsupported claims; limit statements to those explicitly supported by the provided label sections (e.g., 5.1, 5.4, 5.5, 5.6, 5.19, and 17 metabolic/weight monitoring excerpts). Ensure any dosing statements match label-supported regimens and strengths.